Goldman Sachs Group Inc Madrigal Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 239,780 shares of MDGL stock, worth $83.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
239,780
Previous 171,451 39.85%
Holding current value
$83.3 Million
Previous $48 Million 5.94%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$212.22 - $292.96 $14.5 Million - $20 Million
68,329 Added 39.85%
239,780 $50.9 Million
Q2 2024

Aug 13, 2024
BUY
$193.33 - $291.99 $15.4 Million - $23.3 Million
79,662 Added 86.79%
171,451 $48 Million
Q1 2024

May 15, 2024
BUY
$171.37 - $283.23 $1.15 Million - $1.89 Million
6,686 Added 7.86%
91,789 $24.5 Million
Q4 2023

Feb 13, 2024
BUY
$120.4 - $237.13 $1.05 Million - $2.06 Million
8,691 Added 11.37%
85,103 $19.7 Million
Q3 2023

May 14, 2024
SELL
$146.04 - $225.78 $1.27 Million - $1.96 Million
-8,691 Reduced 10.21%
76,412 $11.2 Million
Q3 2023

Nov 14, 2023
BUY
$146.04 - $225.78 $891,282 - $1.38 Million
6,103 Added 8.68%
76,412 $11.2 Million
Q2 2023

May 14, 2024
SELL
$203.88 - $312.0 $14.8 Million - $22.7 Million
-72,682 Reduced 50.83%
70,309 $16.2 Million
Q2 2023

Aug 14, 2023
SELL
$203.88 - $312.0 $14.8 Million - $22.7 Million
-72,682 Reduced 50.83%
70,309 $16.2 Million
Q1 2023

May 14, 2024
SELL
$231.06 - $307.08 $4.81 Million - $6.39 Million
-20,800 Reduced 12.7%
142,991 $34.6 Million
Q1 2023

May 11, 2023
SELL
$231.06 - $307.08 $4.81 Million - $6.39 Million
-20,800 Reduced 12.7%
142,991 $34.6 Million
Q4 2022

May 14, 2024
SELL
$58.39 - $296.54 $969,916 - $4.93 Million
-16,611 Reduced 9.21%
163,791 $47.5 Million
Q4 2022

Feb 13, 2023
SELL
$58.39 - $296.54 $969,916 - $4.93 Million
-16,611 Reduced 9.21%
163,791 $47.5 Million
Q3 2022

May 14, 2024
BUY
$60.57 - $79.51 $7.74 Million - $10.2 Million
127,776 Added 242.8%
180,402 $11.7 Million
Q3 2022

Nov 10, 2022
BUY
$60.57 - $79.51 $7.74 Million - $10.2 Million
127,776 Added 242.8%
180,402 $11.7 Million
Q2 2022

May 14, 2024
SELL
$58.04 - $100.2 $1.88 Million - $3.25 Million
-32,477 Reduced 38.16%
52,626 $3.77 Million
Q2 2022

Aug 15, 2022
BUY
$58.04 - $100.2 $234,365 - $404,607
4,038 Added 8.31%
52,626 $3.77 Million
Q1 2022

May 16, 2022
SELL
$55.89 - $101.89 $3.18 Million - $5.8 Million
-56,891 Reduced 53.94%
48,588 $4.77 Million
Q4 2021

Feb 14, 2022
SELL
$72.34 - $95.09 $3.59 Million - $4.73 Million
-49,691 Reduced 32.02%
105,479 $8.94 Million
Q3 2021

Nov 10, 2021
BUY
$78.35 - $105.02 $12.2 Million - $16.3 Million
155,170 New
155,170 $12.4 Million

Others Institutions Holding MDGL

# of Institutions
296
Shares Held
22M
Call Options Held
819K
Put Options Held
640K
View Full List

About MADRIGAL PHARMACEUTICALS, INC.

MDGL Quotes by TradingView
  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email